SCHEMBL3446199

SCHEMBL3446199

COC(=O)c1ccc(N)c(C#N)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.56
MAPT P10636 8/20 0.56
ALDH1A1 P00352 7/20 0.56
HPGD P15428 7/20 0.56
GAA P10253 3/20 0.56
HSD17B10 Q99714 3/20 0.56
GLA P06280 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
ATM Q13315 1/20 0.56
USP2 O75604 1/20 0.51
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA12 O43570 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
XDH P47989 1/20 0.47
HDAC1 Q13547 1/20 0.46
NPC1 O15118 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4950780 0.87 KDM4E (0.60) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL8148281 0.84 CA1 (0.52) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL3726391 0.84 PTPN1 (0.56) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL3726394 0.84 PTPN1 (0.56) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL9889383 0.84 CYP4A11 (0.49) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL4891137 0.83 KDM4E (0.56) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL28880690 0.83 CA1 (0.50) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL17594423 0.83 LMNA (0.54) KDM4EMAPTALDH1A1HSD17B10CA1
SCHEMBL399625 0.81 CA1 (0.62) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL4598114 0.81 KDM4E (0.57) KDM4EMAPTALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731306-A1 CYSTOBACTAMID DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2026-04-29 EP disclosed
EP-4605392-A1 METHODS FOR TREATING CANCER Antares Therapeutics, Inc. (US) 2025-08-27 EP disclosed
WO-2025003147-A1 CYSTOBACTAMID DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2025-01-02 WO disclosed
CN-113121393-B Aromatic amide compound and application thereof in medicines 广东东阳光药业股份有限公司 2024-08-09 CN disclosed
WO-2024086809-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
WO-2023284651-A1 N-(2-AMINOPHENYL)BENZAMIDE COMPOUND AND APPLICATION THEREOF 南京明德新药研发有限公司 2023-01-19 WO disclosed
CN-111727186-B Biheterocyclic substituted pyridine-2 (1H) -ketone derivative, preparation method and medical application thereof 上海海雁医药科技有限公司 2022-11-08 CN disclosed
US-20220289679-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-15 US disclosed
EP-4005637-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2022-06-01 EP disclosed
CN-113121393-A Aromatic amide compound and application thereof in medicines 广东东阳光药业有限公司 2021-07-16 CN disclosed
US-20090182140-A1 Alicyclic Heterocyclic Compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-07-16 US disclosed
WO-2009080555-A2 CARBOXYL- OR HYDROXYL- SUBSTITUTED BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-07-02 WO disclosed
EP-1537075-B1 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH AS (DK) 2009-07-01 EP disclosed
US-20090163552-A1 CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-06-25 US disclosed
EP-1970373-A1 ALICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2008-09-17 EP disclosed
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers NEUROSEARCH A/S (DK) 2006-07-20 US disclosed
EP-1537075-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2005-06-08 EP disclosed
WO-2004022529-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed
US-5188641-A Acrylic polymers for dyeing textiles, plastics, paints, paper and lacquers; colorfastness; intensity IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-23 US disclosed
US-4763371-A Coloration process for applying a colored polymer containing units derived from an organic dye IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182140-A1 Alicyclic Heterocyclic Compound CCR4, CCR1, HRH4 KDM4E 657/4885MAPT 4753/4885ALDH1A1 1767/4885
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers KIT, ORAI1, CACNA1C KDM4E 1042/4885MAPT 4510/4885ALDH1A1 1538/4885
US-20220289679-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC KDM4E 2610/4885MAPT 772/4885ALDH1A1 1563/4885
US-20090163552-A1 CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES NR1H4, GPBAR1, SLC10A1 KDM4E 2127/4885MAPT 4722/4885ALDH1A1 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.